Latest Breaking News On - Luc demarre - Page 1 : comparemela.com

ABIONYX Pharma Announces Its 2023 Full-Year Financial Results

ABIONYX Pharma Announces Its 2023 Full-Year Financial Results
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLuc demarreCyrille tupinRegulatory news

ABIONYX Pharma Successfully Manufactures a Third Batch of Recombinant Human apoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

18.12.2023 - Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the .

Lang schwarzCyrille tupinLuc demarreAbionyx pharma share stockAbionyx pharma share chartBionyx pharma share kursBionyx pharma share aktie

ABIONYX Pharma Completes a Capital Increase in Favor of Categories of Persons

ABIONYX Pharma Completes a Capital Increase in Favor of Categories of Persons
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Arthur rouillCyrille tupinEmmanuel huynhNicolas fossiezJean louis dasseuxSadok belmokhtarLouis victor delouvrierLuc demarreChief executive officerAnnual general meetingGeneral regulationsDes marchRegistration documentVictor delouvrier

ABIONYX Pharma Provides Further Details on the Setting up of Its Equity-Linked Financing Facility

Regulatory News: ABIONYX Pharma, (FR0012616852 ABNX PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the

France generalLouis victor delouvrierLuc demarreNicolas fossiezArthur rouillCyrille tupinEuropean unionRegulatory newsVictor delouvrierGefallene big techs

ABIONYX Pharma Provides Further Details on the Setting up of Its Equity-Linked Financing Facility

29.05.2023 - Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world s only natural recombinant ApoA-I, .

Luc demarreLang schwarzCyrille tupinAbionyx pharma share stock